PRP Injection Therapy

Platelet-Rich Plasma (PRP) therapy concentrates growth factors from the patient's own blood to reduce joint and tendon inflammation and stimulate tissue repair. Commonly used for knee arthritis, tennis elbow, ligament injuries, and muscle tears.

Platelet-Rich Plasma (PRP) therapy at Pinnacle Orthopaedic Group is a minimally invasive regenerative treatment that leverages the body's own healing biology to address musculoskeletal pain and injury. The procedure begins with a simple blood draw from the patient, which is then processed in a centrifuge to concentrate the platelets — the cells responsible for releasing growth factors that orchestrate tissue repair and reduce inflammation. The resulting PRP preparation contains a significantly higher concentration of platelets than normal blood, delivering a targeted dose of healing signals directly to damaged tissue. At Pinnacle, PRP is typically administered under imaging guidance to ensure precise injection placement, particularly for intra-articular (within-joint) applications. PRP therapy is well-suited for a range of musculoskeletal conditions including knee osteoarthritis, hip joint degeneration, shoulder rotator cuff tendinopathy, tennis elbow (lateral epicondylitis), golfer's elbow (medial epicondylitis), Achilles tendinopathy, plantar fasciitis, and ligament sprains. It is an attractive option for patients who have not responded adequately to physiotherapy, oral medications, or corticosteroid injections but wish to avoid or delay surgery. The procedure is performed on an outpatient basis and typically takes around 30–45 minutes including preparation time. Most patients require 1–3 sessions spaced several weeks apart, with clinical improvement often becoming noticeable 4–8 weeks after treatment as the tissue remodels. Because PRP is derived from the patient's own blood, the risk of allergic reaction or immune rejection is very low, making it a safe option for most patients. Pinnacle's orthopaedic surgeons evaluate each case thoroughly to determine whether PRP is the most appropriate regenerative option or whether nStride APS or BMAC therapy may offer greater benefit.